| [1] |
Kim HJ, Jung SH, Kim JJ, et al. New-onset diabetes mellitus after heart transplantation: incidence, risk factors and impact on clinical outcome[J]. Circ J, 2017, 81(6):806-814.
|
| [2] |
Jenssen T, Hartmann A. Post-transplant diabetes mellitus in patients with solid organ transplants[J]. Nat Rev Endocrinol, 2019, 15(3):172-188.
|
| [3] |
Aksoy N. Weight gain after kidney transplant[J]. Exp Clin Transplant, 2016, 14(Suppl 3):138-140.
|
| [4] |
Vanhove T, Remijsen Q, Kuypers D, et al. Drug-drug interactions between immunosuppressants and antidiabetic drugs in the treatment of post-transplant diabetes mellitus[J]. Transplant Rev, 2017, 31(2):69-77.
|
| [5] |
Snowsill TM, Moore J, Mujica Mota RE, et al. Immunosuppressive agents in adult kidney transplantation in the National Health Service: a model-based economic evaluation[J]. Nephrol Dial Transplant, 2017, 32(7):1251-1259.
|
| [6] |
Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J]. N Engl J Med, 2016, 375(19):1834-1844.
|
| [7] |
Azoulay L, Suissa S. Sulfonylureas and the risks of cardiovascular events and death: a methodological meta-regression analysis of the observational studies[J]. Diabetes Care, 2017, 40(5):706-714.
|
| [8] |
Haidinger M, Antlanger M, Kopecky C, et al. Post-transplantation diabetes mellitus: evaluation of treatment strategies[J]. Clin Transplant, 2015, 29(5):415-424.
|
| [9] |
Haidinger M, Werzowa J, Hecking M, et al. Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation--a randomized, double-blind, placebo-controlled trial[J]. Am J Transplant, 2014, 14(1): 115-123.
|
| [10] |
Naylor KL, Jamal SA, Zou G, et al. Fracture incidence in adult kidney transplant recipients[J]. Transplantation, 2016, 100(1):167-175.
|
| [11] |
Halden TA, Egeland EJ, Åsberg A, et al. GLP-1 restores altered insulin and glucagon secretion in post-transplantation diabetes[J]. Diabetes Care, 2016, 39(4):617-624.
|
| [12] |
Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial[J]. Lancet, 2018, 392(10157): 1519-1529.
|
| [13] |
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2016, 375(4):311-322.
|
| [14] |
Eisenga MF, Zelle DM, Sloan JH, et al. High serum PCSK9 is associated with increased risk of new-onset diabetes after transplantation in renal transplant recipients[J]. Diabetes Care, 2017, 40(7):894-901.
|
| [15] |
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J]. N Engl J Med, 2015, 373(22):2117-2128.
|
| [16] |
Cehic MG, Muir CA, Greenfield JR, et al. Efficacy and safety of empagliflozin in the management of diabetes mellitus in heart transplant recipients[J]. Transplant direct, 2019, 5(5):e450.
|
| [17] |
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes[J]. N Engl J Med, 2017, 377(7):644-657.
|
| [18] |
Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2019, 380(4):347-357.
|
| [19] |
Sommerer C, Witzke O, Lehner F, et al. Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials[J]. BMC Nephrol, 2018, 19(1):237.
|
| [20] |
Karpe KM, Talaulikar GS, Walters GD. Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients[J]. Cochrane database Syst Rev, 2017(7):CD006750.
|